Trials / Recruiting
RecruitingNCT06554795
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- DualityBio Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Detailed description
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DB-1419 | Administered Injection of Vein (I.V.) |
Timeline
- Start date
- 2024-09-03
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2024-08-15
- Last updated
- 2026-03-27
Locations
36 sites across 3 countries: United States, Australia, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06554795. Inclusion in this directory is not an endorsement.